No Data
Hisense Pharmaceuticals: Report for the third quarter of 2024
Haisco Pharmaceutical (001367.SZ) released its performance for the first three quarters, with a net income of 86.95 million yuan, a year-on-year increase of 20.89%.
Haisco Pharma (001367.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...
Haisen Pharmaceutical (001367.SZ) plans to invest in the construction project of Haisen Pharmaceutical's new factory area, with a total investment amount for the first phase not less than 2 billion yuan.
Haisco Pharmaceutical (001367.SZ) announced to promote the company's global strategy development, enhance the main business operations, and strengthen expertise to achieve...
Private Companies Invested in Zhejiang Haisen Pharmaceutical Co., Ltd. (SZSE:001367) up 22% Last Week, Insiders Too Were Rewarded
Haisen Pharmaceutical (001367.SZ) plans to grant 2.3 million restricted stocks at a grant price of 12.65 yuan per share.
Hansen Pharmaceuticals (001367.SZ) disclosed the 2024 restricted stock incentive plan (draft), and the company plans to grant stocks to encourage...
Hesen Pharmaceutical (001367.SZ): Currently, aluminum sucrose sulfate has obtained the CEP certificate issued by the European Directorate for the Quality of Medicines (EDQM), and has completed the DMF registration in the United States (status is A status)
On September 10th, Guotonghui reported that Hesen Pharmaceuticals (001367.SZ) held a performance briefing on September 10, 2024. The company was asked about the latest progress on the product category of aluminum sucrose sulfate, which is a product that the company has a strong competitive advantage in. The company stated that it has accumulated rich technical research and development foundation in the long-term production management practice of aluminum sucrose sulfate. The synthesis process of aluminum sucrose sulfate is stable and environmentally friendly, with low overall cost. Aluminum sucrose sulfate has obtained the Certificate of Suitability for the European Pharmacopoeia from EDQM and has completed the DMF registration in the United States (status is in an Approved status). The formulated products of the company's partner have been launched in the United States and sales have been growing rapidly. The reporting period.
No Data
No Data